© 2025 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
In PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma buparlisib and paclitaxel was not associated with a survival improvement.
Among patients with PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), treatment with buparlisib and paclitaxel was not associated with an improvement in overall survival (OS) compared with paclitaxel alone, clinical trial results have shown.
Phase 3 results of the BURAN trial were presented during the 2025 ESMO Congress in Berlin.
Findings showed that the median OS with buparlisib plus paclitaxel was 9.6 months compared with 9.7 months with paclitaxel alone in this patient population.
Overall survival: The length of time from the start of treatment that patients are still alive.
Overall response rate: The percentage of patients whose cancer shrinks or disappears after treatment.
Progression-free survival: The length of time during and after treatment that a patient lives with cancer without it getting worse.
ECOG performance status: A scale doctors use to measure how a patient’s illness affects their daily living and ability to care for themselves.
“The buparlisib plus paclitaxel combination arm has a numerically higher overall response rate, but there was no increase in progression-free survival compared to the paclitaxel-only arm,” lead study author Dr. Denis Souliéres, full professor of medicine at the Université de Montréal, Canada, said in an oral presentation during the meeting. “Translational data will permit to explore if molecular subgroups derive significant benefit.”
Buparlisib is an oral pan-PI3K inhibitor that targets all four isoforms of class 1 PI3K. Prior phase 1b data showed that buparlisib and paclitaxel showed clinical activity in patients with taxane-pretreated advanced solid tumors. Additionally, data from the phase 2 BERIL-1 trial showed a progression-free survival (PFS) improvement with buparlisib and paclitaxel versus placebo and paclitaxel, as well as an OS improvement in patients with recurrent or metastatic squamous cell carcinoma of head and neck who experienced failure of one prior platinum-based therapy.
To be eligible for enrollment, patients had to have recurrent or metastatic HNSCC and have received a prior PD-1/PD-L1 inhibitor in the recurrent/metastatic setting, one to two prior lines of therapy, and an ECOG performance status of 0 or 1.
A total 487 patients were randomly assigned between April 2021 and November 2023 to receive buparlisib at 100 mg once daily plus paclitaxel at 80 mg/m2 on days 1, 8, and 15 every three weeks or paclitaxel alone at the same dosage.
Most patients who discontinued the combination (98.5% for both agents) did so because of disease progression (buparlisib, 38.7%; paclitaxel, 39.9%) followed by side effects (38.1%; 35.6%). In the paclitaxel-alone arm, 98.8% of patients discontinued paclitaxel due to disease progression (54.9%) and side effects (17.7%).
Regarding baseline characteristics across both arms, 29.8% of patients were HPV positive, approximately half were from Europe (50.1%), and the majority were male (80.3%). The median age was 61.5 years, and 63.4% were White; most were not Hispanic or Latino (85.6%). HPV positivity only of the oropharynx was in 19.8% of patients who received the buparlisib combination and 17.7% of those who received chemotherapy alone.
A total 42.4% and 39% of patients, respectively, previously received a PD-1/PD-L1 inhibitor alone or in combination with non–platinum-based therapy, while 39.3% and 45.1% of patients received the immunotherapy concurrently with platinum-based chemotherapy. A total 16.7% and 15.9% of patients received them in sequence with platinum-based chemotherapy. Furthermore, 70% and 68.3% of patients on buparlisib and paclitaxel alone, respectively, had metastatic disease at study entry.
Additional efficacy data showed that the confirmed ORR was 30.3% with buparlisib/paclitaxel compared with 20.7% with paclitaxel alone; the unconfirmed ORRs were 44.3% and 28%, respectively. When assessed via investigator, the confirmed ORRs were 29.7% versus 24.4% and unconfirmed ORRs were 44.6% and 28%.
The median DOR was 5.6 months with buparlisib versus 9.1 months with paclitaxel alone; per investigator assessment, the median DOR was 7 months versus 6.7 months, respectively.
The median PFS was 4.1 months in each arm by investigator assessment, the median PFS was 4.3 months compared with 4.2 months, respectively.
Regarding safety, grade 3 (severe) or higher side effects occurred in 87.5% and 59.4% of patients of the combination versus paclitaxel alone arms; treatment-related grade 3 or higher side effects were reported in 71% and 33.8%, respectively. A total 60.1% of these side effects were related to buparlisib; 60.4% were paclitaxel related in the combination arm versus 33.8% in the monotherapy arm.
Side effects that led to study drug discontinuation occurred in 45.2% and 16.9% of patients in the buparlisib combination and paclitaxel alone groups, respectively. A total 37.7% of those in the combination group were buparlisib related; on the combination arm, 35.2% were related to paclitaxel, and 16.9% were related to paclitaxel on the monotherapy arm. Side effects of special interest occurred in 88.2% and 75% of patients, respectively.
Souliéres noted that there were no characteristics that were a factor in OS improvement with the combination versus paclitaxel alone, except for a potential survival advantage in patients with HPV-positive oropharynx cancer versus other HPV status and primary site of cancer. North American patients also had a significantly higher OS advantage with buparlisib/paclitaxel compared with Asian Pacific patients and European patients.
“There were more HPV-positive patients that were North American patients compared to what we saw in Asia and Europe, but I will remind you that the HPV positivity did not specifically translate into an OS in the overall analysis,” Souliéres commented.
Souliéres concluded that the immunotherapy-refractory HNSCC patient population remains one with significant unmet need.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Related Content:
